Exploring Emerging Targeted Therapies in Relapsed Small Cell Lung Cancer

This activity was originally presented live at the Oncology Pharmacists Connect conference in Austin, TX on June 20, 2024.

Program Description

Small cell lung cancer (SCLC) is typically more aggressive and more difficult to treat than non—small cell lung cancer due to rapid tumor growth and quick development of resistance. This session focuses on therapeutic updates in SCLC, emphasizing advancements in treatment strategies and the management of toxicities. Expert faculty will review the epidemiology of SCLC, risk factors, and challenges with limited frontline treatments. The emergence of second-line therapies, combination therapies, and potential novel treatment regimens will be discussed. Oncology pharmacists are central figures in the health care team as they participate in therapy discussions and assist in managing treatment-related toxicities. Included patient case scenarios present considerations for applying these strategies, evaluating new therapeutic approaches, and mitigating adverse effects of therapy.

Target audience: Oncology pharmacists

Type of activity: Application
Release date: June 25, 2024
Expiration date: June 25, 2024

Time to complete activity: 1.0 hour

Learner level: Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Compare the pharmacology and toxicology of novel and emerging treatments for relapsed extensive-stage small cell lung cancer (ES-SCLC)
• Analyze the latest clinical evidence for second-line and subsequent systemic therapies in ES-SCLC
• Determine interventions and therapeutic monitoring strategies for treatment-related toxicities associated with systemic therapies in ES-SCLC

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-24-207-H01-P. The activity is available for CE credit through June 25, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Shelby Merchant, PharmD, BCOP, has the following financial relationship with a commercial interest to disclose:
Advisory Board: Daiichi Sankyo

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Jordyn P. Higgins, PharmD, BCOP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Crissy Wilson; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.


Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms